Overview

Antiviral Prophylaxis in a Burn Population

Status:
Withdrawn
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
A prospective, randomized trial to calculate incidence of Herpes Simplex Virus in an in-patient burn population and determine efficacy of prophylactic antiviral therapy to prevent viral infection and/or reactivation. Hypothesis is that antiviral prophylaxis will be effective in reducing HSV infection/reactivation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Southern Illinois University
Treatments:
Acyclovir
Antiviral Agents